Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Phase 2 Study to Evaluate the Safety, Efficacy, and Tolerability of MLS-101 in Subjects With Uncontrolled Hypertension

NCT05001945 is registered in ClinicalTrials.gov with Mineralys Therapeutics Inc. as lead sponsor.

NCT NCT05001945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05001945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Phase 2 Study to Evaluate the Safety, Efficacy, and Tolerability of MLS-101 in Subjects With Uncontrolled Hypertension
Lead sponsor
Mineralys Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2021
Completion date
October 7, 2022
Enrollment
200 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, renal